Safety and Efficacy of T10430 Eye Drops in Controlling Paediatric Myopia Progression (NCT07522242) | Clinical Trial Compass
RecruitingPhase 2
Safety and Efficacy of T10430 Eye Drops in Controlling Paediatric Myopia Progression
Jordan200 participantsStarted 2026-01-21
Plain-language summary
Axial myopia is a type of nearsightedness that happens when the eye is too long from front to back. This causes distant vision to be blurry. Axial myopia tends to start during childhood and worsens over time (as the eyes continue to grow longer). This can lead to serious eye-related conditions later in life. The aim of T10430 treatment is to stop or slow this progression during childhood and therefore, prevent more serious complications. Animal studies using drugs with a similar mechanism of action as T10430 have demonstrated positive safety results. This study aims to better understand the safety and potential effectiveness of T10430 in children with axial myopia.
Who can participate
Age range6 Years – 11 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. \- Informed consent signed and dated.
✓. \- Male or female participant between ≥ 6 and \< 12 years old.
✓. \- Spherical equivalent refractive error (SER) of at least -1.00D and no more than -6.00D in each eye as measured by cycloplegic autorefraction.
✓. \- IOP \< 21mmHg in each eye.
✓. \- Distant BCVA equal or better than 0.1 LogMAR \[≤ 0.1 LogMAR (equivalent to ≥ 20/25 Snellen)\] in each eye.
Exclusion criteria
✕. Known intolerance to administration of eye drops.
✕. Astigmatism \> 1.50D as measured by cycloplegic autorefraction.
✕. Anisometropia ≥ 1.50D as measured by cycloplegic autorefraction.
✕. Current or history of amblyopia or manifest strabismus including intermittent tropia.
✕. Current or history of glaucoma.
What they're measuring
1
Measure of the occurrence of treatment-emergent adverse events (TEAEs).
Timeframe: From the time the participant signs the assent and their legual guardian the informed consent and throughout the entire study: up to approximately 60 weeks, including a maximum treatment period of 56 weeks and a 4 weeks follow-up period.